Top 5 Opportunities for Generic/Biosimilar Drugs in the Pharmaceuticals Market, 2019 ReportHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Top 5 Opportunities for Generic/Biosimilar Drugs in the Pharmaceuticals Market, 2019 ReportGlobeNewswireJanuary 8, 2020ReblogShareTweetShareDublin, Jan. 08, 2020 (GLOBE NEWSWIRE) -- The "Top 5 Generic Opportunities in Pharmaceuticals to Watch in 2019: Perspective for the Future" report has been added to ResearchAndMarkets.com's offering.
The report includes:An overview of top five opportunities for generic or biosimilar drugs in pharmaceuticals market 2019Coverage of generics and discussion on their characteristicsInformation on Hatchmann-Wax act and its effect on market competitiveness impacting pricing and development of original drugsInsights on the key challenges and opportunities in the development of generics or biosimilar drugsDescription of product class, mechanism of action, indications and contraindicationsClinical and generic development of the prominent productsDetailed patent analysis i.e. expiry and exclusivity, regulations and policies and patent expiry and market impactProfiles of key competitors engaged in the development of generic and biosimilarsKey Topics Covered
Chapter 1 IntroductionChapter 2 Perspectives of Generics and Biosimilar BusinessOverview of Generics and BiosimilarsGenericsTypes of GenericsBiosimilarsLifecycle of a Biosimilar DrugDevelopment of a BiosimilarManufacturing of a BiosimilarPreclinical Studies and Validation of a BiosimilarClinical TrialsGenerics vs. BiosimilarsMarket Landscape of Generics and BiosimilarsCompetitive Landscape of Generics and BiosimilarsTrendsStructure of the Generics IndustryBiosimilars Competitive LandscapeBio-intellectual CompaniesOpportunistic CompaniesEmerging Trends in Biosimilar Industry StructureChapter 3 Patents & Patent CliffsPatents and IPSupplementary Protection Certificates Patent Regulations in Favor of Branded Biologics Patent Regulations in Favor of Biosimilars - Emerging Trends Chapter 4 Regulation of Generics and Biosimilars BusinessUnited StatesEuropean UnionEU Marketing Authorization SystemsTypes of ApplicationsRegulation of BiosimilarsEU ProvisionsEvolving Situation in the U.S.User FeesDefensive Strategies by Big PharmaAuthorized GenericsUser FeesChanging Climate for GenericsSituation in EuropeChapter 5 Product Profile AnalysisOverviewProfile AnalysisXolairMechanism of ActionIndications and ContraindicationDosage and Administration Historical Net Sales and Growth Rates of Xolair for NovartisTimeline of Key Events-Xolair (Omalizumab)Key Regulatory ApprovalsPricing and Annual Cost of Xolair Associated with TreatmentFactors Favoring Generic/Biosimilar Development of XolairBiosimilar Clinical DevelopmentsProfiles Key Companies engaged in the Business/Development of Xolair and Biosimilar OmalizumabCompanies Developing Biosimilar Version of OmalizumabRevlimidMechanism of ActionIndications and ContraindicationDosage and Administration Historical Net Sales and Growth RatesTimeline of Key Events-Revlimide (Lenalilomide)Pricing and Annual Cost of Revlimid Associated with TreatmentFactors Influencing Generic Development Business & Legal ChallengesFDA's Campaign of Naming and Shaming of Branded Pharmaceuticals Adopting Anti-Trade PracticesRevlimid Generics Development/Marketed DrugsCompany ProfilesGeneric Manufacturers of RevlimidOrenciaMechanism of ActionIndications and ContraindicationDosage and Administration Historical Net Sales and Growth Rates of Orencia for Bristol-Meyers SquibbTimeline of Key Events-OrenciaPricing and Annual Cost of Orencia Associated with TreatmentFactors Favoring Generic/Biosimilar Development of OrenciaBiosimilar Clinical DevelopmentsProfiles Key Companies Engaged in the Business/Development of Xolair and Biosimilar OmalizumabCompanies Developing Biosimilar Version of OmalizumabPradaxaMechanism of ActionIndications Adverse ReactionDosage and Administration Historical Net Sales and Growth Rates of PradaxaClinical Development Timeline of Key Events-Pradaxa (Dabigatran)Pricing and Annual Cost of Pradaxa Factors Favoring Generic Development of PradaxaGenerics Clinical DevelopmentsProfiles of the Pradaxa ManufacturerGeneric Manufacturer of PradaxaGilenyaMechanism of ActionIndicationsDosage and Administration Historical Net Sales and Growth Rates of Gilenya for NovartisTimeline of Key Events-GilenyaPricing and Annual Cost of Gilenya Associated with TreatmentFactors Favoring Generic/Biosimilar Development of GilenyaGeneric Clinical DevelopmentsProfiles Key Companies Engaged in the Business/Development of GilenyaCompanies Developing Generic Version of GilenyaChapter 6 ConclusionImproved Understanding of Pharmaceutical TechnologiesAccess to Pharmaceutical Technologies and Production MethodsShift in the Business Model of Pharmaceutical IndustryChallengesFuture PerspectivesList of TablesTable 1: List of Biosimilars Produced in E. ColiTable 2: List of Biosimilars Produced in Mammalian CellsTable 3: Number of Approved Biosimilars, by TypeTable 4: Generics vs. BiosimilarsTable 5: List of Key ProductsTable 6: Sales of Xolair, Through 2018Table 7: Approved Indications for Use of RevlimidTable 8: Sales of Revlimid, Through 2018Table 9: Dosage Recommendation Per Patient WeightTable 10: Sales of Orencia, Through 2018Table 11: Sales of Pradaxa, Through 2018Table 12: Sales of Gilenya, Through 2018List of FiguresFigure 1: Xolair Key Events, 2003-2018, Post 2020Figure 2: Revlimid Key Events, 2005-2019Figure 3: Orencia Key Events, 2005-2019Figure 4: Pradaxa Key Events, 2008-2017Figure 5: Gilenya Key Events, 2010-2019
For more information about this report visit https://www.researchandmarkets.com/r/lhtesResearch and Markets also offers Custom Research services providing focused, comprehensive and tailored research.CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextMomenta's (MNTA) Q4 Loss Wider than Expected, Sales BeatZacksThe Michael J. Fox Foundation for Parkinson's Research Announces New Chairman of the Board, Biopharma Leader Skip IrvingPR NewswireNonprofit drug development company starts GoFundMe for emergency funds to treat coronavirusPR NewswireDana-Farber teams up with investment firm to develop cancer drugsAmerican City Business JournalsBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoMost face masks won’t protect you from the coronavirusYahoo Finance'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo Finance